InfuSystem (NYSE:INFU) Upgraded at StockNews.com

by · The Cerbat Gem

InfuSystem (NYSE:INFU – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Friday.

Separately, B. Riley began coverage on shares of InfuSystem in a research note on Thursday, September 26th. They set a “buy” rating and a $13.00 price objective for the company.

Read Our Latest Stock Report on InfuSystem

InfuSystem Trading Up 6.4 %

Shares of INFU traded up $0.47 during trading hours on Friday, reaching $7.81. 102,498 shares of the stock traded hands, compared to its average volume of 47,135. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.64 and a current ratio of 2.07. InfuSystem has a 52-week low of $5.74 and a 52-week high of $10.99. The company’s 50-day simple moving average is $6.59. The company has a market capitalization of $166.51 million, a P/E ratio of 781.78 and a beta of 1.45.

InfuSystem (NYSE:INFU – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The firm had revenue of $33.70 million for the quarter. InfuSystem had a net margin of 0.28% and a return on equity of 0.70%. On average, research analysts forecast that InfuSystem will post 0.17 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers grew its holdings in InfuSystem by 13.8% during the 2nd quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock worth $121,000 after acquiring an additional 2,145 shares in the last quarter. ARS Investment Partners LLC boosted its stake in shares of InfuSystem by 11.4% during the second quarter. ARS Investment Partners LLC now owns 33,510 shares of the company’s stock valued at $229,000 after purchasing an additional 3,422 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in InfuSystem by 6.1% during the second quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock valued at $641,000 after buying an additional 5,391 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in InfuSystem by 28.0% during the third quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company’s stock worth $223,000 after buying an additional 7,295 shares during the period. Finally, Williams & Novak LLC bought a new position in shares of InfuSystem in the 3rd quarter worth $70,000. 71.13% of the stock is currently owned by institutional investors.

About InfuSystem

(Get Free Report)

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

See Also